Enanta Pharmaceuticals Announces New Preclinical Data for its Respiratory Virology Programs to be Presented at the 12th International RSV Symposium

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that new preclinical data related to its respiratory syncytial virus (RSV) program, as well as new virology methods used for its RSV and human metapneumovirus (hMPV) programs, will be presented at the 12^th International RSV Symposium being held on September 29 – October 2, 2022 at the ICC Belfast in Northern Ireland, United Kingdom.

Oral Presentation

Date: Saturday, October 1, 2022

Time: 9:45 – 10:00 a.m. British Summer Time (BST) / 4:45 – 5:00 a.m. Eastern Daylight Time (EDT)

Title: “EDP-323, a Novel L-Protein Inhibitor, for the Treatment of Respiratory Syncytial Virus”

Presenter: Michael Rhodin, Ph.D.

Poster Presentations

Date: Friday, September 30, 2022

Time: 6:00 – 8:00 p.m. BST / 1:00 – 3:00 p.m. EDT

Title: “In Vivo Efficacy of EDP-323, a Novel L-Protein Inhibitor, for the Treatment of Respiratory Syncytial Virus”

Presenter: Rachel Levene, Ph.D.

Date: Friday, September 30, 2022

Time: 6:00 – 8:00 p.m. BST / 1:00 – 3:00 p.m. EDT

Title: “An Improved Toolkit for In Vitro hMPV Characterization”

Presenter: Joyce Sweeney Gibbons, Ph.D.

Date: Friday, September 30, 2022

Time: 6:00 – 8:00 p.m. BST / 1:00 – 3:00 p.m. EDT

Title: “Evaluation of a Human 3D Airway Tissue Culture Model for the Study of Respiratory Syncytial Virus Infection and the Development of Antiviral Drugs”

Presenter: Nicole McAllister

Posters will be available to view on the conference platform during the conference. Further information about the 12^th International RSV Symposium can be found here.

About Enanta Pharmaceuticals, Inc.

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Enanta’s research and development programs include clinical candidates currently in development for the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV). Enanta is also conducting research in human metapneumovirus (hMPV).

Enanta’s research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic HCV infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET^® (U.S.) and MAVIRET^® (ex-U.S.) (glecaprevir/pibrentasvir). Please visit www.enanta.com for more information.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220922005202/en/